We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares in Affimed surged 140 percent after the company announced an agreement with Roche's Genentech unit to develop and commercialise NK cell engager-based immunotherapeutics to treat multiple cancers.